Screener
Theravance Biopharma TBPH Other operating expenses
Other operating expenses at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development (1) | 5,829 | 11,452 |
| Selling, general and administrative (1) | 17,720 | 18,370 |
| Restructuring expenses (1) (2) | 3,633 | — |
| Total expenses | 27,182 | 29,822 |
| Loss from operations | (9,483) | (14,434) |
| Interest expense (non-cash) | — | (643) |
| Interest and other income, net | 3,013 | 939 |
| Loss before income taxes | (6,470) | (14,138) |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's other operating expenses?
- Theravance Biopharma (TBPH) reported other operating expenses of $27.18M in Q1 2026.
- How has Theravance Biopharma's other operating expenses changed year-over-year?
- Theravance Biopharma's other operating expenses decreased by 8.9% year-over-year, from $29.82M to $27.18M.
- What is the long-term trend for Theravance Biopharma's other operating expenses?
- Over 4 years (2021 to 2025), Theravance Biopharma's other operating expenses has grown at a -22.8% compound annual growth rate (CAGR), from $313.1M to $111.07M.
- What does other operating expenses mean?
- Residual operating expenses not classified into specific categories, serving as a catch-all for miscellaneous operating costs.
Ask your AI about Theravance Biopharma's other operating expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude